As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology (NASDAQ: POAI) offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of over 150K tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise.
Ticker:
POAI
Exchange:
POAI
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Minnesota
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PeDAL
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
